How have OGEN shares performed in 2023?

Oragenics' stock was trading at $0.1051 at the beginning of 2023. Since then, OGEN stock has increased by 3,323.2% and is now trading at $3.5978. View the best growth stocks for 2023 here .

Are investors shorting Oragenics?

Oragenics saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 52,400 shares, a decline of 25.9% from the October 15th total of 70,700 shares. Based on an average trading volume of 17,400 shares, the short-interest ratio is presently 3.0 days. Currently, 2.5% of the shares of the stock are short sold. View Oragenics' Short Interest .

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSEAMERICAN:OGEN) released its earnings results on Thursday, November, 9th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.01 million for the quarter.

When did Oragenics' stock split?

Oragenics's stock reverse split on the morning of Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Imunon (CLSN) , Jaguar Health (JAGX) , Biocept (BIOC) , OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Heat Biologics (HTBX) , Idera Pharmaceuticals (IDRA) and Achieve Life Sciences (ACHV) .

How do I buy shares of Oragenics?

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Oragenics Stock Price, News & Analysis (NYSEAMERICAN:OGEN)

$3.60

+0.09 (+2.57%)

(As of 11/28/2023 ET)

Compare

Today's Range: $3.50
▼
$3.60
50-Day Range: $2.94
▼
$4.18
52-Week Range: $2.60
▼
$12.54

Volume: 2,359 shs
Average Volume: 15,973 shs
Market Capitalization: $9.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest

About Oragenics Stock (NYSEAMERICAN:OGEN)

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

OGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OGEN Stock News Headlines

November 26, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Oragenics (NYSEAMERICAN:OGEN)

November 20, 2023 | americanbankingnews.com

Oragenics (NYSEAMERICAN:OGEN) Research Coverage Started at StockNews.com

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 6, 2023 | finance.yahoo.com

Oragenics, Inc. (UAV.F)

November 2, 2023 | finance.yahoo.com

Oragenics Issues Update to Shareholders

October 5, 2023 | marketwatch.com

Oragenics Shares Rise 15% After Deal to Buy Some Odyssey Health Assets

October 5, 2023 | finance.yahoo.com

Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate

October 2, 2023 | msn.com

Oragenics, AVITA Medical among healthcare movers

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

September 29, 2023 | marketwatch.com

Stocks to Watch: Oragenics, Natuzzi, Syndax Pharmaceuticals

September 29, 2023 | finance.yahoo.com

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

August 7, 2023 | finance.yahoo.com

Oragenics, Inc. Announces Private Placement

June 5, 2023 | finance.yahoo.com

Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM

March 29, 2023 | finance.yahoo.com

Oragenics to Participate in the World Vaccine Congress Washington

March 14, 2023 | finance.yahoo.com

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

March 8, 2023 | finance.yahoo.com

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

March 1, 2023 | finance.yahoo.com

Oragenics Looks To Boost Potency Of Its Nasal COVID-19 Vaccine With New Licensing Pact

March 1, 2023 | finance.yahoo.com

Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

February 3, 2023 | financialpost.com

Oragenics, Inc. Regains Compliance with NYSE American

December 23, 2022 | finance.yahoo.com

Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split

December 22, 2022 | finance.yahoo.com

Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate

December 20, 2022 | finance.yahoo.com

Oragenics, Inc. Receives NYSE American Notice

December 19, 2022 | financialpost.com

Oragenics, Inc. Announces New Chair

October 24, 2022 | finance.yahoo.com

Oragenics to Participate in the 2022 BioFlorida Annual Conference

September 30, 2022 | benzinga.com

Oral & Dental Probiotics Market Size & Shares by 2027 | Revenue, Cost Analysis, Gross Margins, Future Inv - Benzinga

September 9, 2022 | morningstar.com

Oragenics Inc OGEN Stock Quote

September 7, 2022 | reuters.com

OGEN.P - Oragenics Inc | Stock Price & Latest News | Reuters

See More Headlines

Receive OGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 11/28/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:OGEN
CUSIP: N/A
CIK: 1174940
Web: www.oragenics.com
Phone: 813-286-7900
Fax: 813-286-7904
Employees: 6
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,290,000.00
Net Margins: N/A
Pretax Margin: -26,700.00%
Return on Equity: -132.48%
Return on Assets: -93.84%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.57
Quick Ratio: 5.57

Sales & Book Value

Annual Sales: $130,000.00
Price / Sales: 71.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.64 per share
Price / Book: 0.64

Miscellaneous

Outstanding Shares: 2,570,000
Free Float: 1,937,000
Market Cap: $9.25 million
Optionable: Not Optionable
Beta: 0.53

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Ms. Kimberly M. Murphy (Age 60)
President, CEO & Director
Comp: $497.03k
Ms. Janet Huffman (Age 51)
CFO, Secretary & Treasurer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

OGEN Stock Analysis - Frequently Asked Questions

How have OGEN shares performed in 2023?: Oragenics' stock was trading at $0.1051 at the beginning of 2023. Since then, OGEN stock has increased by 3,323.2% and is now trading at $3.5978.
View the best growth stocks for 2023 here.
Are investors shorting Oragenics?: Oragenics saw a decline in short interest in the month of October. As of October 31st, there was short interest totaling 52,400 shares, a decline of 25.9% from the October 15th total of 70,700 shares. Based on an average trading volume of 17,400 shares, the short-interest ratio is presently 3.0 days. Currently, 2.5% of the shares of the stock are short sold.
View Oragenics' Short Interest.
How were Oragenics' earnings last quarter?: Oragenics, Inc. (NYSEAMERICAN:OGEN) released its earnings results on Thursday, November, 9th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.01 million for the quarter.
When did Oragenics' stock split?: Oragenics's stock reverse split on the morning of Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Oragenics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Imunon (CLSN), Jaguar Health (JAGX), Biocept (BIOC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Amarin (AMRN), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA) and Achieve Life Sciences (ACHV).
How do I buy shares of Oragenics?: Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:OGEN) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial